Replies to post #90673 on Rivulet Media Inc (fka RIVU)

[cjstocksup]

BMSN ADVISORY BOARD | REGEN BIOPHARMA, INC.

Weiping Min, M.D.
Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.

Vladimir Bogin M.D.
Dr. Bogin is the President and CEO of Cromos Pharma, a contract research organization that specializes in biopharmaceutical clinical outsourcing. He was formerly the Director of Boehringer Ingelheim in charge of the phase IV program for Dabigatran Etexilate. He studied at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry.

David James Graham White, M.D., Ph.D.
Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University.

[Rocco!!]

True, the recent PRs national and internationally for BMSN has definitely help expose them as a tremendous potential for investors.

Don’t quote me on this but I won’t be surprised if BMSN makes the big jump and trades on the big boards in the near future. However, one step at the time; incidentally as many already know BMSN has completed their goals they set up for themselves and what’s on the agenda next for BMSN?